drugset / Trial / NCT00309036

Safety and Efficacy of Recombinant Grass Pollen Allergen Cocktail in the Treatment of Allergic Rhinoconjunctivitis

NCT00309036 ↗

Phase 3 Completed Allergopharma GmbH & Co. KG
RandomizedParallel-groupDouble-blindTreatment

Summary

The trial is performed to assess efficacy and safety of a recombinant grass Pollen allergen cocktail in allergic rhinoconjunctivitis

Timeline

Start
2004-01
Primary completion
2006-09
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Recombinant grass pollen Protein / enzyme biologic — —

Indications